Mycophenolate Mofetil · Regulatory label update

FDA supplemental approval: Mycophenolate Mofetil (REMS)

U.S. Food and Drug Administration · July 29, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

The FDA approved a supplemental REMS (Risk Evaluation and Mitigation Strategy) for mycophenolate mofetil 250 mg capsules (oral) manufactured by Sandoz on 29 July 2026. This is a regulatory action establishing risk management requirements; it does not contain or report clinical trial efficacy, safety data, or comparative outcomes.

What was studied

Regulatory label update.

Key findings

Safety

This record is a regulatory approval action only and does not contain clinical trial results, efficacy data, safety outcomes, or comparative evidence.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for mycophenolate mofetil; this is a regulatory action, not a clinical trial, and does not report efficacy or comparative clinical outcomes.

Reported figures

Quoted from the source exactly as published.

Approval date2026-07-29

Dose and formulationMYCOPHENOLATE MOFETIL 250 MG, CAPSULE, ORAL

Submission classREMS

Caveats

This record is a regulatory approval action only and does not contain clinical trial results, efficacy data, safety outcomes, or comparative evidence.
The specific requirements of the REMS are not detailed in this record.
No information on the clinical indication, patient population affected, or rationale for the REMS is provided.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

This is a regulatory action record, not a clinical study.

Directness

insufficient

Record does not report clinical trial data or direct patient outcomes.

Consistency

insufficient

No comparative or confirmatory data provided in this regulatory record.

Risk of bias

insufficient

Risk of bias assessment does not apply to regulatory approval records.

Sample adequacy

insufficient

No clinical sample or study population described in this regulatory document.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Drugs@FDA record for application ANDA065379. This is a regulatory action record, not a clinical study. Brand name: MYCOPHENOLATE MOFETIL. Active ingredient: MYCOPHENOLATE MOFETIL. Sponsor: SANDOZ. Submission type: SUPPL (supplement). Submission class: REMS. Approval status date: 2026-07-29. Products: MYCOPHENOLATE MOFETIL, CAPSULE, ORAL, MYCOPHENOLATE MOFETIL 250MG.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Mycophenolate MofetilSandoz